Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gilead Sciences
(NQ:
GILD
)
131.65
+0.81 (+0.62%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 1, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
5,517,174
Open
130.00
Bid (Size)
131.40 (900)
Ask (Size)
133.10 (200)
Prev. Close
130.84
Today's Range
129.01 - 132.36
52wk Range
95.30 - 157.29
Shares Outstanding
1,253,809,440
Dividend Yield
2.40%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences
May 01, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
2 Nasdaq 100 Stocks with Solid Fundamentals and 1 We Find Risky
May 01, 2026
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a win...
Via
StockStory
Performance
YTD
+8.3%
+8.3%
1 Month
-6.2%
-6.2%
3 Month
-7.3%
-7.3%
6 Month
+9.9%
+9.9%
1 Year
+27.5%
+27.5%
More News
Read More
Gilead Sciences Stock Outlook: Is Wall Street Bullish or Bearish?
April 30, 2026
Via
Barchart.com
Topics
ETFs
$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today
↗
April 29, 2026
Via
Benzinga
Gilead Sciences Inc (NASDAQ:GILD): A Balanced Dividend Play with Strong Financial Health and Profitability
↗
April 25, 2026
Via
Chartmill
Gilead Sciences (NASDAQ:GILD): A Value Screen Candidate with Strong Profitability
↗
April 20, 2026
Via
Chartmill
Opes Wealth Sells Its Entire FIXD Stake -- Is This $9.3 Million Bond ETF Exit A Signal?
↗
April 29, 2026
Via
The Motley Fool
Topics
Bonds
ETFs
Regulatory Compliance
U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir
April 29, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel
April 28, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
3 Healthcare Stocks That Pay You While You Wait for the Growth
↗
April 27, 2026
Via
The Motley Fool
Topics
Intellectual Property
2 Large-Cap Stocks to Consider Right Now and 1 We Turn Down
April 24, 2026
Via
StockStory
Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026
April 22, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
What's Going On With Arcus Biosciences Stock On Wednesday?
↗
April 22, 2026
Via
Benzinga
Eli Lilly Snags $7 Billion Cancer Deal To Rival Gilead, J&J, Others
↗
April 20, 2026
Via
Investor's Business Daily
Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
↗
April 14, 2026
Via
Benzinga
PEPFAR and The Global Fund Make Additional Investment in Gilead’s Lenacapavir for HIV Prevention to Further Expand Access
April 14, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
1 Profitable Stock for Long-Term Investors and 2 Facing Challenges
April 14, 2026
Via
StockStory
Q4 Earnings Highs And Lows: Gilead Sciences (NASDAQ:GILD) Vs The Rest Of The Therapeutics Stocks
April 12, 2026
Via
StockStory
Topics
Artificial Intelligence
Gilead Expands Partnership With Tempus AI To Power Cancer Discoveries
↗
April 10, 2026
Via
Benzinga
Topics
Artificial Intelligence
Gilead Sciences Solidifies Oncology Future with $5 Billion Acquisition of ADC Innovator Tubulis
April 09, 2026
Via
MarketMinute
Topics
Bonds
Gilead Expands Tempus AI Partnership To Boost Oncology Pipeline
↗
April 09, 2026
Via
Benzinga
Topics
Artificial Intelligence
Gilead Acquisition Spree Continues With $3 Billion Tubulis Deal
↗
April 07, 2026
Via
Benzinga
Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline
April 07, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Extends Tender Offer for Arcellx as Biotech M&A Sentiment Faces a Reality Check
April 06, 2026
Via
MarketMinute
Gilead Extends Tender Offer to Acquire Arcellx
April 01, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Frequently Asked Questions
Is Gilead Sciences publicly traded?
Yes, Gilead Sciences is publicly traded.
What exchange does Gilead Sciences trade on?
Gilead Sciences trades on the Nasdaq Stock Market
What is the ticker symbol for Gilead Sciences?
The ticker symbol for Gilead Sciences is GILD on the Nasdaq Stock Market
What is the current price of Gilead Sciences?
The current price of Gilead Sciences is 131.65
When was Gilead Sciences last traded?
The last trade of Gilead Sciences was at 05/01/26 04:00 PM ET
What is the market capitalization of Gilead Sciences?
The market capitalization of Gilead Sciences is 165.06B
How many shares of Gilead Sciences are outstanding?
Gilead Sciences has 165B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.